Cargando…

Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies

INTRODUCTION: X-linked hypophosphataemia (XLH) is a rare, genetic renal phosphate-wasting disease, resulting from excess fibroblast growth factor 23 (FGF23) activity, which has a progressive and profound impact on patients throughout life. The monoclonal anti-FGF23 antibody, burosumab, is a subcutan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubota, Takuo, Namba, Noriyuki, Tanaka, Hiroyuki, Muroya, Koji, Imanishi, Yasuo, Takeuchi, Yasuhiro, Kanematsu, Masanori, Sun, Wei, Seino, Yoshiki, Ozono, Keiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887240/ https://www.ncbi.nlm.nih.gov/pubmed/36719566 http://dx.doi.org/10.1007/s12325-022-02412-x

Ejemplares similares

Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial
por: Namba, Noriyuki, et al.
Publicado: (2022)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia
por: Imanishi, Yasuo, et al.
Publicado: (2020)

Long-term outcomes for Asian patients with X-linked hypophosphataemia: rationale and design of the SUNFLOWER longitudinal, observational cohort study
por: Kubota, Takuo, et al.
Publicado: (2020)

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
por: Briot, Karine, et al.
Publicado: (2021)

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
por: Kamenicky, Peter, et al.
Publicado: (2023)

Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
por: Brandi, Maria Luisa, et al.
Publicado: (2022)

First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia
por: Cheong, Hae Il, et al.
Publicado: (2018)

Beneficial Effect of Oral Bisphosphonate Treatment on Bone Loss Induced by Chronic Administration of Furosemide without Alteration of Its Administration and Urinary Calcium Loss
por: Kubota, Takuo, et al.
Publicado: (2006)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

Severe hypophosphataemia after intravenous iron administration
por: Anand, Gurpreet, et al.
Publicado: (2017)

Endocrinological and phenotype evaluation in a patient with acrodysostosis
por: Ueyama, Kaoru, et al.
Publicado: (2017)

Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
por: Padidela, Raja, et al.
Publicado: (2021)

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
por: Imel, Erik A, et al.
Publicado: (2023)

An overgrowth disorder associated with excessive production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene
por: Miura, Kohji, et al.
Publicado: (2013)

Clinical Practice Guidelines for Hypophosphatasia*
por: Michigami, Toshimi, et al.
Publicado: (2020)

A Japanese Male Patient with ‘Fibular Aplasia, Tibial Campomelia and Oligodactyly’: An Additional Case Report
por: Kitaoka, Taichi, et al.
Publicado: (2009)

Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report
por: Miyaoka, Daichi, et al.
Publicado: (2020)

A Spectrum of Clinical Presentations in Seven Japanese Patients with Vitamin D Deficiency
por: Kubota, Takuo, et al.
Publicado: (2006)

Wnt Signaling in Bone
por: Kubota, Takuo, et al.
Publicado: (2010)

Isolated hypophosphataemia as an early marker of primary hyperparathyroidism
por: Alexander, John, et al.
Publicado: (2021)

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

Life-threatening hypophosphataemia in a cirrhotic patient with jaundice
por: Moutzouri, Elisavet, et al.
Publicado: (2011)

Hypophosphataemia among Severely-malnourished Children: Case Series
por: Yoshimatsu, Shoji, et al.
Publicado: (2012)

Left Ventricular Hypertrophy in Patients with X-Linked Hypophosphataemia
por: Castellano-Martinez, Ana, et al.
Publicado: (2022)

Pheochromocytoma complicated by cyanotic congenital heart disease: a case report
por: Yamamoto, Keiko, et al.
Publicado: (2016)

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report
por: Takeyari, Shinji, et al.
Publicado: (2019)

Prevalence of Pseudohypoparathyroidism and Nonsurgical Hypoparathyroidism in Japan in 2017: A Nationwide Survey
por: Takatani, Rieko, et al.
Publicado: (2023)

An Overgrowth Disorder Associated with Excessive Production of cGMP Due to a Gain-of-Function Mutation of the Natriuretic Peptide Receptor 2 Gene
por: Miura, Kohji, et al.
Publicado: (2012)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia
por: Weber, Thomas J, et al.
Publicado: (2022)

Incidence, severity and timing of hypophosphataemia in Glasgow Royal Infirmary ICU
por: Gilhooly, CJ, et al.
Publicado: (2009)

Acute onset quadriparesis following oesophagectomy due to isolated hypophosphataemia
por: Naik, Vibhavari M, et al.
Publicado: (2019)

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia
por: Haffner, Dieter, et al.
Publicado: (2019)

Clinical factors associated with severe hypophosphataemia after kidney transplant
por: Ralston, Maximilian R., et al.
Publicado: (2021)

Hepatic osteodystrophy with hypophosphataemia and elevated fibroblast growth factor‐23
por: Ng, Nicholas Beng Hui, et al.
Publicado: (2022)

Treatment of Hypophosphatemic Rickets with Phosphate and Active Vitamin D in Japan: A Questionnaire-based Survey
por: Fujiwara, Makoto, et al.
Publicado: (2013)

Molecular Bases of Diseases Characterized by Hypophosphatemia and Phosphaturia: New Understanding
por: Ozono, Keiichi, et al.
Publicado: (2006)

A Male Patient with Humoral Hypercalcemia of Malignancy (HHM) with Leukocytosis Caused by Cutaneous Squamous Cell Carcinoma Resulting from Recessive Dystrophic Epidermolysis Bullosa
por: Miura, Kohji, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ncppscma2gf7q8en0g1trpnsk2